COVID-19 and mucormycosis superinfection: the perfect storm.
Jaffar A Al-TawfiqSaad AlhumaidAbeer N AlshukairiMohamad-Hani TemsahMazin BarryAbbas Al MutairAli A RabaanAwadh Al-OmariRaghavendra TirupathiManaf AlQahtaniSalma AlBahraniKuldeep DhamaPublished in: Infection (2021)
With the ongoing COVID-19 pandemic and increasing number of critically ill patients infected with SARS-CoV-2, it is important to develop a risk-based approach for patients at risk of mucormycosis based on the epidemiological burden of mucormycosis, prevalence of diabetes mellitus, COVID-19 disease severity and use of immune modulating agents including the combined use of corticosteroids and immunosuppressive agents in patients with cancer and transplants.